Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage African Trypanosomiasis - Overview African Trypanosomiasis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes African Trypanosomiasis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type African Trypanosomiasis - Companies Involved in Therapeutics Development Merck & Co Inc Novartis AG Sanofi Scynexis Inc African Trypanosomiasis - Drug Profiles AN-5568 - Drug Profile Product Description Mechanism Of Action R&D Progress CBL-0137 - Drug Profile Product Description Mechanism Of Action R&D Progress DDD-100097 - Drug Profile Product Description Mechanism Of Action R&D Progress fexinidazole - Drug Profile Product Description Mechanism Of Action R&D Progress GNF-6702 - Drug Profile Product Description Mechanism Of Action R&D Progress melarsoprol hydroxypropylbetadex - Drug Profile Product Description Mechanism Of Action R&D Progress MS-08 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides for Sleeping Sickness - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Infectious Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Sleeping Sickness - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress African Trypanosomiasis - Dormant Projects African Trypanosomiasis - Discontinued Products African Trypanosomiasis - Product Development Milestones Featured News & Press Releases Aug 30, 2016: UGA researchers discover a drug for a tropical disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for African Trypanosomiasis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 African Trypanosomiasis - Pipeline by Merck & Co Inc, H2 2017 African Trypanosomiasis - Pipeline by Novartis AG, H2 2017 African Trypanosomiasis - Pipeline by Sanofi, H2 2017 African Trypanosomiasis - Pipeline by Scynexis Inc, H2 2017 African Trypanosomiasis - Dormant Projects, H2 2017 African Trypanosomiasis - Discontinued Products, H2 2017

Merck & Co Inc Novartis AG Sanofi Scynexis Inc